[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Université Catholique de Louvain\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":612},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,46,67,96,122,142,163,190,218,237,259,280,301,328,350,391,410,434,456,476,496,523,543,561,588],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641595","acute-effects-of-post-exercise-hyperoxia-on-recovery-in-cycling-100641595",false,"NCT07659301","Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling","Inclusion Criteria:\n\n* Road cyclists competing in Elite 2 (Elite without professional contract) or Under-23 (U23) categories or equivalent \\[Participation in national-level Belgian competitions within the previous 12 months. No specific ranking, finishing position, or performance threshold is required.\\]\n* ≥ 2 consecutive years of cycling experience at regional or national level, with structured and periodized training\n* Cycling-specific training volume ≥ 8 h a week over the preceding 10 weeks\n* Stable training load in the weeks preceding inclusion, with no major changes due to injury, illness, or abnormal overload\n* Measured VO₂max ≥ 60 ml\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* Presence of significant cardiovascular, pulmonary, neurological, ENT, or metabolic disease, including but not limited to: Uncontrolled arterial hypertension (systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg) ; Unstable heart disease or decompensated cardiomyopathy\n* Contraindications to hyperbaric exposure, including: Untreated pneumothorax, History of spontaneous pneumothorax without medical clearance ; Pulmonary conditions associated with air trapping (e.g. emphysema or bullous lung disease), or abnormal thoracic imaging when indicated ; Recent thoracic surgery\n* Neurological contraindications, including epilepsy, history of oxygen-induced seizures, or recent seizure activity, and any association with cannabis use\n* Ear, sinus, or Eustachian tube disorders preventing adequate pressure equalization, including active infection or history of severe barotrauma\n* Severe claustrophobia incompatible with chamber exposure",true,"MALE","18 Years","40 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study examines whether exposition to hyperbaric oxygen after a road-race simulation can help competitive cyclists recover and perform better the following day.\n\nHyperbaric oxygen, which involves breathing oxygen inside a pressurized chamber, is used as a recovery method in elite and professional sport. Its effectiveness, however, remains controversial: despite this widespread use, there is a lack of solid scientific evidence that a single HBO session after strenuous endurance exercise actually improves recovery, or that clarifies how the amount of oxygen exposure influences any benefit.\n\nThe study includes healthy male road cyclists between 18 and 40 years of age who compete at the national level in Belgium. After completing a fatiguing cycling session, each participant is randomly assigned to one of four groups receiving different levels of oxygen exposure during recovery.\n\nTwo groups breathe oxygen under increased pressure inside a chamber at either 2.5 or 1.4 atmospheres absolute. A third group breathes oxygen at normal pressure. The fourth group receives a sham condition that reproduces the treatment setting without active oxygen exposure.\n\nThe study is double-blind, meaning that neither the participants nor the researchers assessing the outcomes know which condition each participant receives.\n\nThe main goal is to determine whether a single session of post-exercise HBO improves next-day endurance performance, and whether higher oxygen exposure produces greater effects.\n\nThe researchers also collect blood samples and physiological measurements to better understand how the body recovers.",[28,29,30,31,32],"Athletic Performance","Hyperbaric Oxygenation","Physical Endurance","Muscle Fatigue","Oxidative Stress","RECRUITING","2026-06-15",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":22},"2026-07-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Université Catholique de Louvain","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":45},"100627814","assessing-chronic-pain-patient-preferences-100627814","NCT07453524","Assessing Chronic Pain Patient Preferences","Assessing Chronic Pain Patient Preferences Regarding the Analgesic Effect Relative to the Side Effects of Analgesic Drugs","patientPREF","Inclusion Criteria:\n\n* Aged over 18 years.\n* Being treated with pain medication.\n* (Chronic-)Pain for at least 3 months.\n* Capacity to understand and provide an informed consent form.\n\nExclusion Criteria:\n\n* Insufficient French or English language skills.\n* Epilepsy treated by an anti-epileptic.\n* Alzheimer's disease.\n* Parkinson's disease","ALL",{"count":56,"type":22},200,[25],"The goal of this study is to ask chronic pain patients their preferences regarding which side effects of pain medications are least acceptable in relation to their pain relief benefits. This information may help in the selection of improved treatment options in the future.",[60],"Chronic Pain","2026-06-11",{"date":34,"type":37},{"date":64,"type":37},"2026-03-15",{"date":41,"type":22},{"name":43,"class":44},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100640436","change-in-platelet-lipid-metabolism-and-procoagulant-phenotype-induced-by-cardiopulmonary-bypass-impact-on-postoperative-inflammatory-response-and-bleeding-complications-during-cardiac-surgery-100640436","NCT07630987","Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.","PLACARD","Inclusion Criteria:\n\n* Adult patients (≥ 18 years old) suffering from coronary disease and\u002For severe valvular dysfunction (mitral or aortic) undergoing elective coronary angiography or cardiac surgery with cardiopulmonary bypass.\n\nExclusion Criteria:\n\n* Uninterrupted preoperative dual antiplatelet therapy\n* Active chronic inflammatory disease\n* Recent chemotherapy or immunotherapy (\\\u003C 3 months)\n* Active solid malignancy\n* History of hematologic malignancy\n* Hemophilia or other coagulopathy\n* History of thrombocytopenia (\\\u003C 100,000 platelets\u002Fmm³)\n* Recent administration of thrombopoietin receptor agonist or immunoglobulins\n* History of thrombopathy, thrombocytosis, or myeloproliferative syndrome\n* History of heparin-induced thrombocytopenia (HIT)\n* Cirrhosis or hepatic fibrosis (with or without hypersplenism)\n* History of splenectomy, regardless of initial indication\n* History of systemic autoimmune disease (e.g., systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, systemic vasculitis)\n* Recent major surgery (\\\u003C 3 months)\n* Severe renal insufficiency (eGFR ≤ 30 mL\u002Fmin\u002Fm²) with or without dialysis\n* Recent or chronic corticosteroid therapy\n* Recent acute coronary syndrome, STEMI type (\\\u003C 3 months)\n* Urgent surgery or procedure\n* Preoperative hemodynamic instability",{"count":75,"type":22},100,[25],"The PLACARD research project aims to investigate the impact of CPB-induced platelet modifications during cardiac surgery on the post-operative inflammatory response and bleeding complications. Our objectives are to study the impact of CPB on the formation of procoagulant platelets, to assess changes in platelet lipid profile and bioenergetics before, during and after cardiac surgery, and to connect the ex-vivo observations to post-operative clinical and biological parameters of these patients during their stay in cardiovascular intensive care unit.",[79,80,81],"Cardiac Surgery","Cardiopulmonary Bypass","Platelet Activation",[83,84,85,86],"Procoagulant platelets","Platelet lipidomics","Postoperative inflammation","Postoperative bleeding","NOT_YET_RECRUITING","2026-06-02",{"date":90,"type":37},"2026-06-05",{"date":92,"type":22},"2026-05-15",{"date":94,"type":22},"2030-01",{"name":43,"class":44},{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":45},"100639473","assessment-of-a-new-tool-to-measure-tongue-muscle-function-100639473","NCT07625761","Assessment of a New Tool to Measure Tongue Muscle Function","TOM1","Inclusion Criteria:\n\n* Being a healthy adult aged 18 to 65 years old\n* Being able to understand and speak French\n\nExclusion Criteria:\n\n* Being diagnosed with a cardiorespiratory or neuromuscular disease\n* Being diagnosed with obstructive sleep apnea-hypopnea syndrome\n* Any reason preventing the participant from completing the measurement protocol (e.g., oral pain, severe cognitive impairment, lack of cooperation, illiteracy)\n* Being involved in an oropharyngeal rehabilitation program\n* Having dysphagia","65 Years",{"count":105,"type":22},58,[25],"The Iowa Oral Performance Instrument (IOPI) is currently the reference tool for assessing tongue muscle function, measuring the pressure exerted by the tongue on an air-filled bulb. However, several limitations reduce its precision and clinical relevance. To overcome these, the TOngue Manometer (TOM) has been developed. This crossover study compares the two devices in healthy adults, hypothesizing that the TOM's interface will enable participants to produce higher maximal tongue pressure and endurance values, closer to their ground truth.",[109],"Healthy",[111,109,112,113],"Adults","tongue","muscles","2026-05-28",{"date":116,"type":37},"2026-06-04",{"date":118,"type":22},"2026-05-30",{"date":120,"type":22},"2027-12-01",{"name":43,"class":44},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":103,"enrollmentInfo":129,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":45},"100623853","predicting-weight-loss-after-pharmacological-or-surgical-treatment-in-patients-with-obesity-100623853","NCT07402031","Predicting Weight Loss After Pharmacological or Surgical Treatment in Patients With Obesity","Research of Predictive Factors of Weight Loss After Pharmacological or Surgical Treatment in Patients Suffering From Obesity","Inclusion criteria:\n\n* Age between 18 and 65 years\n* Obesity, with bariatric surgery indicated after a multidisciplinary evaluation in case of surgical treatment.\n* Good physical and mental health, enabling informed consent.\n* French speaker\n\nExclusion criteria:\n\n* Legal protection\n* Pregnancy or breastfeeding\n* History of bariatric surgery (except gastric banding, provided it was removed more than five years ago).\n* Acute or progressive chronic disease\n* Alcohol consumption of more than 20 g\u002Fday\n* Inflammatory bowel disease;\n* Digestive autonomic diabetic neuropathy.\n* Consumption of dietary supplements (stanols, probiotics, prebiotics or omega-3).\n* Following a vegan or gluten-free diet or being lactose intolerant.\n* Fibre consumption \\>30 g\u002Fday\n* Recent change in antidiabetic medication within the past 3 months.",{"count":75,"type":22},"OBSERVATIONAL","As with other nutritional strategies, the clinical response to bariatric surgery can be highly variable, with weight regain being a frequent occurrence. Recent evidence on anti-obesity medication indicate similar inter-individual variability in clinical response. Among multiples factors, co-occurrence of eating disorders such as binge eating disorder has been implicated in insufficient clinical response. Improving our ability to predict how patients will respond to obesity treatment is necessary in order to tailor the care pathways we offer. The mechanisms involved in disturbances of eating behaviour before and after surgery remain largely unknown. This study aims to identify the predictive factors of weight loss after pharmacological or surgical treatment, as well as the cognitive and biological mechanisms that mediate this effect.",[133],"Obesity & Overweight","2026-05-11",{"date":136,"type":37},"2026-05-14",{"date":138,"type":37},"2026-05-05",{"date":140,"type":22},"2036-01",{"name":43,"class":44},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":45},"100640417","identification-of-mpn-specific-antigens-and-anti-mpn-tcrs-in-myeloproliferative-neoplasm-100640417","NCT07590986","Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm","Inclusion Criteria:\n\n* Patients previously diagnosed or suspected of having PV, ET, pre-PMF, overt PMF, or an unclassifiable MPN.\n* Patients not previously diagnosed with a haematological disease as controls\n\nExclusion Criteria:\n\n* Patients with any other hematological malignancy.",{"count":149,"type":22},150,"The goal of this observational study is to learn how the immune system responds to myeloproliferative neoplasms (MPN) in adults with known or suspected MPN. Researchers also want to identify immune cells that could help develop future immune-based treatments for MPN.\n\nThe main questions it aims to answer are:\n\n* Are there T cells in the bone marrow that can recognize MPN cells?\n* Which targets (antigens) on MPN cells are recognized by these immune cells?\n* Can researchers identify T cell receptors (TCRs) that may be used in future TCR-based therapies?\n\nResearchers will study samples from adults with polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-PMF, or unclassifiable MPN. Samples from healthy donors without blood disorders will also be included for comparison.\n\nBy providing blood and bone marrow samples, participants will:\n\n* Allow researchers to study immune cells and genetic material from these samples\n* Allow researchers to perform laboratory tests to study how immune cells recognize MPN cells\n\nResearchers will use laboratory methods such as genetic sequencing, cell analysis, and cell culture experiments to better understand immune responses in MPN.\n\nParticipants will not receive direct medical benefit from this study. The results may help researchers better understand MPN and support the future development of immune-based therapies.",[152,153,154,155],"Myeloproliferative Neoplasm (MPN)","Polycytemia Vera","Essential Thrombocythemia (ET)","Primary Myelofibrosis (PMF)","2026-05-08",{"date":92,"type":37},{"date":159,"type":22},"2026-05",{"date":161,"type":22},"2037-01",{"name":43,"class":44},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":45},"100625253","evaluation-of-the-synergistic-effect-of-combining-a-prebiotic-and-a-postbiotic-on-intestinal-discomfort-100625253","NCT07420231","Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort","Synfood","Inclusion Criteria:\n\n* Woman or man, aged of 18 to 75 years (inclusive);\n* Subject with a measurable level of intestinal discomfort, assessed using a questionnaire inspired by the ROME IV criteria. Eligible participants must meet all of the following conditions:\n\n  1. Experience recurrent abdominal pain present for at least three months and occurring on a regular basis;\n  2. The abdominal discomfort must have a low to moderate impact on quality of life;\n  3. In addition, participants must report at least two of the following gastrointestinal symptoms:\n\n     * Diarrhea\n     * Constipation\n     * Bloating\n     * Excessive flatulence\n     * Nausea\n     * Burping\n     * Sensation of incomplete evacuation\n     * Urgent need to defecate;\n* Body Mass Index (BMI) between 18 and 30 kg\u002Fm² (inclusive);\n* Provision of signed and dated informed consent form;\n* Stated willingness to comply with all study procedures and availability for the duration of the study;\n* Stated willingness to maintain their usual life habits (diet, physical activity, alcohol consumption…);\n* Speaking French.\n\nExclusion Criteria:\n\n* Subject with severe or chronic medical conditions which, in the opinion of the Principal Investigator, could interfere with the evaluation of the study outcomes or compromise participant safety;\n* Subject with a diagnosed gastrointestinal disorder (e.g., Crohn's disease, inflammatory bowel disease, or other chronic digestive conditions);\n* Subject with type 1 or type 2 diabetes;\n* Subject who has taken, within the 28 days prior to the screening visit, or are currently taking, drugs or food supplements intended to improve intestinal comfort, or any other substances that, in the opinion of the Principal Investigator, could interfere with intestinal comfort assessment or transit frequency (prebiotics, laxative, anti-diarrheal, probiotics, postbiotics, synbiotics). These products will also be avoided for the duration of the study;\n* Subject who has taken antibiotics within the 3 months prior to the screening visit. These products will also be avoided for the duration of the study;\n* Subjects undergoing medical treatment which, in the opinion of the Principal Investigator, could interfere with the evaluation of the study criteria or with participant safety: antidepressants, immunosuppressants, antipsychotics, antispasmodics, anxiolytics, neuroleptics. These products will also be avoided for the duration of the study;\n* Subject who had undergone bariatric surgery;\n* Subject consuming more than 5 cups of coffee per day;\n* Subject currently using drugs and\u002For with a history of drug addiction within the past 2 years;\n* Subject with regular alcohol consumption exceeding 3 standard drinks per day (10 g of pure alcohol each), equivalent to 3 glasses of wine (12 cl), 3 glasses of beer (5°, 25cl), or 3 glasses of spirits (18°, 7 cl);\n* Subject with known hypersensitivity to any component of the study product;\n* Subject currently participating in another interventional trial;\n* Woman of childbearing age who is pregnant or breastfeeding or who wishes to become pregnant within the next 12 weeks or who is not using an adequate method of contraception (e.g. oral contraception, IUD, abstinence, ...).","75 Years",{"count":172,"type":22},140,[25],"This study aims to investigate the beneficial effects of the daily consumption of a synbiotic formulation-combining a prebiotic (Berberine, BBR) and a postbiotic (inactivated Bifidobacterium Longum, B.longum)-in adults experiencing intestinal discomfort.",[176,177],"Intestinal Discomfort","Abdominal Pain\u002F Discomfort",[179,180,181],"Intestinal discomfort","B.Longum","Berberine","2026-04-30",{"date":184,"type":37},"2026-05-06",{"date":186,"type":37},"2026-03-16",{"date":188,"type":22},"2026-12-24",{"name":43,"class":44},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":54,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":45},"100576957","prediction-of-tongue-base-obstruction-during-sleep-100576957","NCT06792045","Prediction of Tongue Base Obstruction During Sleep","Tongue Motor Functions Assessment as a Screening Tool for Obstructive Sleep Disordered Breathing in Children","PTOS","Inclusion Criteria:\n\n* Age between 6 and 17 years old\n* Medical diagnosis of obstructive sleep-disordered breathing requiring surgical removal of tonsils (partial or total) and\u002For adenoids\n* Positive Pediatric Sleep Questionnaire (8 or more positive responses)\n* Eligibility for surgical intervention\n\nExclusion Criteria:\n\n* Neurological, cardiac, or respiratory comorbidity other than obstructive sleep-disordered breathing\n* Previous surgery of the upper airway or oral cavity\n* History of or current head or neck cancer\n* Cranial, upper airway, or oral cavity malformation\n* Contraindication to performing endoscopy","6 Years","17 Years",{"count":21,"type":22},"This study investigates the hypothesis that, in children, tongue motor functions can predict both the anatomical site and the degree of upper airway obstruction contributing to obstructive sleep-disordered breathing.",[203],"Obstructive Sleep Disordered Breathing",[205,206,207,208,209,112],"obstructive sleep disordered breathing","pediatrics","sleep","obstructive sleep apnea","snoring","2026-04-28",{"date":212,"type":37},"2026-05-04",{"date":214,"type":37},"2025-08-22",{"date":216,"type":22},"2027-10",{"name":43,"class":44},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":103,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":227,"briefSummary":228,"conditions":229,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":236},"100564292","effects-of-respiratory-muscle-training-on-tongue-muscle-function-100564292","NCT06627283","Effects of Respiratory Muscle Training on Tongue Muscle Function","Effects of Respiratory Muscle Training on Tongue Muscle Function in Healthy Subjects, a Randomized Controlled Trial.","Inclusion Criteria:\n\nCommunity ambulant adults between 18 to 65 years old as of testing day; able to understand French or Dutch (depending on the study's site of inclusion); BMI ≥ 18 and ≤ 30 kg\u002Fm².\n\nExclusion Criteria:\n\nAny diagnosed neuromuscular or cardiorespiratory disease; diagnosed psychiatric or psychological disorders which could affect adherence to or comprehension of instructions; diagnosed eating disorders; previous or ongoing head and neck cancer; diagnosed OSA; presenting a high-risk of sleep-disordered breathing indicated by a NoSAS score of 8 or higher 32 or a STOP-Bang score of 3 or higher 33,34; resting heart rate (HR) \\> 100 beats per minute (bpm) or \\< 50 bpm; resting systolic blood pressure (SBP) \\> 140 or \\< 90 mmHg, diastolic blood pressure (DBP) \\> 90 or \\< 50 mmHg; oxygen saturation (SpO2) \\< 94% at rest on room air. Individuals with abnormal lung function, i.e., forced expiratory volume in 1 second (FEV1) ≤ 80%, forced vital capacity (FVC) ≤ 80%, and FEV1\u002FFVC ≤ 70%, will also be excluded.",{"count":226,"type":22},60,[25],"This study aims to investigate the effects of respiratory muscle training on tongue muscle function in healthy subjects. We hypothesize that respiratory muscle training can improve strength and endurance of the tongue muscles.",[109],{"date":231,"type":37},"2026-04-29",{"date":233,"type":37},"2024-11-04",{"date":39,"type":22},{"name":43,"class":44},3,{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":16,"sex":54,"minAge":245,"maxAge":199,"enrollmentInfo":246,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":45},"100528892","tongue-muscular-assessment-in-healthy-children-100528892","NCT06166680","Tongue Muscular Assessment in Healthy Children","Assessment of Tongue Motor Functions in Healthy Children","TMAC","Inclusion Criteria:\n\n* Being between the ages of 4 and 17\n\nExclusion Criteria:\n\n* Eating disorder\n* Dysphagia\n* Cardiorespiratory disorder\n* Neurological disorder (including neuromuscular disorders)\n* Previous or ongoing obstructive sleep apnea-hypopnea syndrome\n* Previous or ongoing cancer of the head or neck\n* Previous oral or pharyngeal surgery (except for the surgical removal of wisdom teeth)\n* Cranial, oral or upper airway malformation (ex.: nasal cavities, pharynx)\n* Previous or ongoing orthodontic treatment (e.g. braces)\n* More than 33% of positive answers to the Pediatric Sleep Questionnaire (8\u002F22)","4 Years",{"count":247,"type":22},300,"This study aims to obtain normative values for tongue motor functions in healthy children.",[109],[251,252],"Tongue","Motor functions",{"date":212,"type":37},{"date":255,"type":37},"2023-10-07",{"date":257,"type":22},"2026-12-01",{"name":43,"class":44},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":45},"100529129","tongue-protrusion-assessment-in-healthy-adult-flepi-100529129","NCT06169761","Tongue Protrusion Assessment in Healthy Adult (FLEPI)","Assessment of Tongue Protrusion Motor Skills in Healthy Adult","Inclusion Criteria:\n\n* Being 18 years of age or older\n\nExclusion Criteria:\n\n* Eating disorder\n* Dysphagia\n* Cardiorespiratory disorder\n* Previous or ongoing obstructive sleep apnea-hypopnea syndrome\n* Neurological conditions (including neuromuscular disorders)\n* Previous or ongoing cancer of the head or neck\n* Pregnancy\n* Any physical or mental condition that may affect the ability to consent",{"count":247,"type":22},"This study aims to evaluate tongue protrusion motor skills in healthy adults and to assess the reliability of these measurements as well as their validity in relation to other motor functions (handgrip and respiratory muscles).",[109],[251,270,271,272,273],"Motor skills","Protrusion","Strength","Fatigability",{"date":212,"type":37},{"date":276,"type":37},"2023-12-11",{"date":278,"type":22},"2027-05-31",{"name":43,"class":44},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":4},"100627768","research-and-evaluation-of-link-up-dcr-in-brussels-100627768","NCT07452926","Research and Evaluation of Link-Up, DCR in Brussels","Research and Evaluation of Link-Up, Drug Consumption Room in Brussels","Inclusion Criteria:\n\n* user of the DCR Link-Up in Bruxelles\n* agree to participate\n* sufficient command of either French or Dutch\n\nExclusion Criteria:\n\n* Refusal to participate",{"count":288,"type":22},250,[25],"Link-Up is the second Safer Consumption Room (SCMR) to open in the Brussels-Capital Region. SCMRs are public health facilities designed for people who use drugs mainly in public places. They are hygienically safe spaces where users can safely consume the products they have acquired elsewhere without moral judgment, under the supervision of specially trained professional staff. It is a risk reduction facility. Before Link-Up, two other SCMRs were opened in Belgium, including one, GATE, in the Brussels region. These first two SCMRs are currently undergoing scientific evaluation as part of the REVE-DROOM project (approved by the CEHF (2024\u002F28MAI\u002F276, on 06\u002F18\u002F2024) of the \"Drugs\" research program funded by BELSPO (Federal Science Policy). The present project aims to replicate the study of the effects associated with the use of SCMRs on users, as implemented in the evaluation system currently underway at GATE in the new SCMR, Link-Up, with a view to also evaluating its effects. The RELINK study is being conducted at the request of Iriscare, the bicommunal social protection OIP (Public Interests Organization) of the Brussels-Capital Region.\n\nIt is a study based on a natural experiment (i.e., all Link-Up users who agree to participate in the study will be included) and measures various indicators concerning them. The measured indicators primarily concern risky consumption practices (injection, consumption in public spaces, reuse and\u002For sharing of consumption equipment, and other practices that endanger the health of people who use drugs). As secondary effects, the measures concern the sociodemographic and socioeconomic characteristics of the user population, drug-use profiles, level of social integration, quality of life, level of personal recovery, and care needs.\n\nThe analysis of these various indicators will make it possible to describe the profile of Link-up SCS users and to compare it with that of GATE users. In addition, the study design allows for an extension to conduct a cohort follow-up and, therefore, to measure changes associated with the use of the SCS service.\n\nThe current study aims for a sample of at least 250 people recruited within the service. Indicator measurement is carried out using a questionnaire administered with the assistance of the research team and supported by SCS staff. The questionnaire consists of various scales validated in the scientific literature and already used in the REVE-DROOM study.\n\nGiven the similarity of the proposed Link-Up system with the one implemented at GATE, the results of the two Brussels SCSs will be the subject of a comparative analysis.",[292],"Substance Use (Drugs, Alcohol)","2026-02-27",{"date":295,"type":37},"2026-03-05",{"date":297,"type":22},"2026-03",{"date":299,"type":22},"2026-09",{"name":43,"class":44},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":23,"phases":311,"briefSummary":312,"conditions":313,"keywords":315,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":320,"lastUpdatePostDateStruct":321,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":45},"100622537","assessment-of-garp-expression-in-acute-and-chronic-coronary-syndrome-100622537","NCT07384910","Assessment of GARP Expression in Acute and Chronic Coronary Syndrome","Assessment of GARP Expression and Inflammatory Cytokines in Acute and Chronic Coronary Syndrome","GARP-CS","Inclusion Criteria:\n\n* Older than 18 years\n* Able to give informed consent\n* Undergoing coronary angiography.\n\nExclusion Criteria:\n\n* Patients younger than 18 years\n* Unable to give consent\n* Pregnancy\n* Dialysis",{"count":310,"type":22},600,[25],"The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in circulating blood cells from patients with an acute or chronic coronary syndrom. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.",[314],"Atheroma; Heart",[316,317,318,319],"Atheroma","Atherosclerosis","GARP","LRRC32","2026-02-12",{"date":322,"type":37},"2026-02-17",{"date":324,"type":22},"2026-02",{"date":326,"type":22},"2028-01",{"name":43,"class":44},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":16,"sex":54,"minAge":334,"maxAge":199,"enrollmentInfo":335,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":337,"conditions":338,"keywords":340,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":4},"100620638","internalized-symptoms-in-adolescents-with-autism-spectrum-disorder-asd-and-typically-developing-adolescents--gaining-insight-into-coping-strategies-and-the-psychological-processes-involved-100620638","NCT07360223","Internalized Symptoms in Adolescents With Autism Spectrum Disorder (ASD) and Typically Developing Adolescents : Gaining Insight Into Coping Strategies and the Psychological Processes Involved","Inclusion Criteria:\n\n* 12-17 years\n* speak french fluently\n\nExclusion Criteria:\n\n* Intellectual disability","12 Years",{"count":336,"type":22},252,"Introduction: Adolescents with autism spectrum disorder (ASD) have more mental health problems than typically developping adolescents (without ASD). Coping strategies are a key concern for adolescents with ASD in managing depressive and anxiety symptoms. Currently, few studies have examined the coping strategies used by adolescents with ASD. The methodological considerations underscore the need for an assessment method tailored to adolescents with ASD. Finally, although current data are still limited, the results suggest that there may be differences between the coping strategies used by adolescents with ASD and typically developing adolescents, thus calling for more in-depth comparative research.\n\nObjectives: This study aims to validate a coping strategies assessment method adapted for adolescents with ASD (1) and to examine coping strategies associated with internalizing symptoms (2)\n\nPopulation: 252 participants: 84 adolescents with ASD (1), 84 adolescents with autistic traits but no clinical diagnosis of ASD (2), and 84 typically developing adolescents (3). The age range is 12-17 years.\n\nStudy design: The study is divided into two parts: a cross-sectional part (T) and a longitudinal part (L).\n\n* The cross-sectional part will include three meetings spread over a period of approximately three months (approximately one meeting per month).\n* The longitudinal part will consist of a meeting scheduled one year after the last meeting of the cross-sectional part.",[339],"Autism Spectrum Disorder (ASD)",[341],"ASD coping","2026-01-27",{"date":344,"type":37},"2026-01-29",{"date":346,"type":22},"2026-02-01",{"date":348,"type":22},"2031-12-31",{"name":43,"class":44},{"id":351,"slug":352,"hasResults":12,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":16,"sex":54,"minAge":4,"maxAge":357,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":368,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":45},"100622536","immune-cells-role-in-lung-cancer-and-their-use-in-anticancer-immunotherapies-and-inflammatory-lung-disease-100622536","NCT07384897","Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease","IMMUNOPUMON2","Inclusion Criteria:\n\n* Diagnosis of lung cancer\n* Presence of precancerous lung lesions\n* Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \\[COPD\\]) prior to any treatment\n* Control group: individuals without known lung disease\n* Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD)\n* Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected\n\nExclusion Criteria:\n\n* Systemic corticosteroid therapy \\> 10 mg\u002Fday prednisone (or equivalent)\n* Acute infection at the time of inclusion\n* Refusal or inability to provide informed consent (or assent, when applicable)\n* Chronic inflammatory lung disease currently treated with immunosuppressive therapy","80 Years",{"count":359,"type":22},425,[25],"This study aims to better understand the role of immune system cells in lung diseases such as lung cancer, sarcoidosis, and chronic obstructive pulmonary disease (COPD).\n\nThe investigators are studying how these immune cells can sometimes help the body defend itself, but in other cases may contribute to cancer growth or long-term lung inflammation.\n\nAlthough recent treatments like immunotherapy have improved cancer care, only a small proportion of patients currently benefit from these therapies. One goal of this research is to understand why some patients do not respond or develop resistance to treatment.\n\nThe knowledge gained from this study may help researchers develop more effective and personalized treatments for people with lung diseases in the future.",[363,364,365,366,367],"Lung Cancer (Diagnosis)","Sarcoidosis","Chronic Obstructive Pulmonary Disease","Immunotherapy Resistance","Immune Dysregulation",[369,370,364,365,371,372,373,367,374,366,375,376,377,378,379,380,381,382],"lung cancer","Non-Small Cell Lung Cancer","COPD","Immune Cells","Tumor Microenvironment","Immunotherapy","Immune Profiling","Myeloid Cells","Neutrophils","Dendritic Cells","Inflammation","Chronic Inflammation","Immune suppression","Emergency myelopoiesis","2026-01-26",{"date":385,"type":37},"2026-02-03",{"date":387,"type":37},"2025-02-17",{"date":389,"type":22},"2032-02-17",{"name":43,"class":44},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":399,"conditions":400,"keywords":403,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":407,"leadSponsor":409,"locationsCount":45},"100620933","assessment-of-platelet-derived-garp-in-atherosclerotic-disease-100620933","NCT07364058","Assessment of Platelet-derived GARP in Atherosclerotic Disease","CAPGAD","Inclusion Criteria:\n\n* Older than 18 years\n* Able to give informed consent\n* Undergoing carotid or femoral endarterectomy\n\nExclusion Criteria:\n\n* Younger than 18 years\n* Pregnant\n* Dialysis\n* Unable to give informed consent",{"count":56,"type":22},"The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.",[401,402],"Atheroma; Carotid Artery","Atheromatosis",[316,317,318,319],"2026-01-23",{"date":342,"type":37},{"date":324,"type":22},{"date":408,"type":22},"2029-01",{"name":43,"class":44},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":16,"sex":417,"minAge":18,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":45},"100613237","birth-experience-of-women-giving-birth-in-belgium-100613237","NCT07263971","Birth Experience of Women Giving Birth in Belgium","Birth Experiences of Women Giving Birth in French-speaking Belgium and Pathways to Choosing a Place of Birth","Inclusion Criteria:\n\n* have given birth in Belgium\n* have given birth less than a year ago\n* be of legal age\n* volunteer\n\nExclusion Criteria:\n\n* not having given birth once in Belgium\n* being a minor","FEMALE","60 Years",{"count":226,"type":22},"The aim of this research is to understand what motivates women giving birth in Belgium to choose a particular place of birth and their experiences of childbirth. This understanding is made possible by collecting qualitative data from women who have given birth (from the first month after giving birth up to one year postpartum). The objective here is to understand what motivates the choice of place of birth (with a focus on the notion of 'non-choice') and to gain insight into the childbirth experiences of women giving birth in Belgium. The researcher also meets with birth companions (perinatal health professionals and birth companions such as doulas, for example) to understand their professional practice and their choice of workplace (home, birth centre or cottage, traditional hospital ward, university hospital ward, etc.).",[422],"Pregnancy Related",[424,425],"Birthplace Choice","Birth Experience","2025-12-01",{"date":428,"type":37},"2025-12-04",{"date":430,"type":37},"2025-09-08",{"date":432,"type":22},"2028-12-31",{"name":43,"class":44},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":417,"minAge":18,"maxAge":4,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":444,"conditions":445,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":455},"100603867","winq--a-window-of-opportunity-study-with-mitoq-in-breast-cancer-100603867","NCT07142096","WinQ : a Window of Opportunity Study With MitoQ in Breast Cancer","WinQ","Inclusion Criteria:\n\n* Patients must meet the following criteria for study entry:\n* Signed Informed Consent Form (ICF)\n* Ability to comply with protocol, in the investigator's judgment\n* Women aged \\> 18 years (no limit of age)\n* ECOG performance status of 0 or 1\n* Histologically documented TNBC (negative ER, - PR and HER2, status); HER2 negativity will be defined using ISH or IHC assays per ASCO\u002FCAP criteria \\[1\\] and ER\u002FPR negativity will be defined with \\\u003C 10% tumor cells with ER\u002FPgR staining using IHC. Patients with multifocal, multicentric or bilateral tumors are eligible, provided all discrete lesions are sampled and confirmed as triple- negative.\n* Histologically confirmed invasive breast carcinoma\n* Patient agreement to undergo appropriate systemic and surgical management after completion of window treatment\n* Adequate hematologic and end-organ function, as defined by the following laboratory results obtained within 14 days prior to the first study treatment:\n* ANC \\> 1500 cells\u002FµL (without granulocyte colony-stimulating factor support within\n* 2 weeks prior to Cycle 1, Day 1)\n* Platelet count \\> 100,000\u002FµL (without transfusion within 2 weeks prior to Cycle 1, Day 1)\n* Hemoglobin \\> 9.0 g\u002FdL\n* Patients may be transfused to meet this criterion.\n* AST, ALT, and alkaline phosphatase\n* \\\u003C 2.5 x the upper limit of normal (ULN)\n* Serum bilirubin \\\u003C 1.0 x ULN\n* Patients with known Gilbert disease: serum bilirubin level \\\u003C 3 x ULN\n* For patients not receiving therapeutic anticoagulation: INR or aPTT \\\u003C 1.5 x ULN within 14 days prior to initiation of study treatment\n* For patients receiving therapeutic anticoagulation: INR or aPTT within therapeutic limits for at least 1 week immediately prior to initiation of study treatment\n* For patients receiving therapeutic anticoagulation: stable anticoagulant regimen and stable INR during the 14 days immediately preceding initiation of study treatment\n* Creatinine clearance \\> 30 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n* Serum albumin \\> 2.5 g\u002FdL\n* Beta-HCG negative if applicable (cfr infra)\n* Representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 20 unstained slides, with an associated pathology report documenting ER, PR, and HER2 negativity. Tumor tissue should be of good quality based on total and viable tumor content.\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \\\u003C 1% per year, during the treatment period and for at least 1 month after the last dose of MitoQ.\n* A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (\\> 12 continuous months of amenorrhea with no identified cause other than menopause) and has not undergone surgical sterilization (removal of ovaries and\u002For uterus).\n* Examples of contraceptive methods with a failure rate of \\\u003C 1% per year include bilateral tubal ligation, male sterilization, established, hormone-releasing intrauterine devices (IUDs), and copper IUDs.\n* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.\n* Women who are not postmenopausal (\\> 12 months of non-therapy-induced amenorrhea) or have undergone a sterilization procedure must have a negative serum pregnancy test result within 14 days prior to initiation of study food supplement.\n\nExclusion Criteria:\n\n* Men\n* Prior systemic therapy for treatment and prevention of the current breast cancer\n* Known allergy or hypersensitivity to MitoQ\n* Known active viral hepatitis\n* Known human immunodeficiency virus infection with detectable viral load\n* Active tuberculosis\n* Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a food supplement or that may affect the interpretation of the results or render the patient at high risk from treatment complications\n* Pregnant or lactating, or intending to become pregnant during the study Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.\n\nPatients included in the study should not be under fertility preservation procedures because of the unknown effect of the treatment during human pregnancy.",{"count":442,"type":22},20,[25],"The purpose of the study is to validate biomarkers in blood and tumor biopsy in patients with Triple Negative Breast Cancer, after a course of MitoQ treatment",[446],"Breast Cancer","2025-08-18",{"date":449,"type":37},"2025-08-26",{"date":451,"type":37},"2025-07-20",{"date":453,"type":22},"2026-07-20",{"name":43,"class":44},2,{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":4,"eligibilityCriteria":461,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":357,"enrollmentInfo":462,"targetDuration":4,"studyType":23,"phases":464,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":469,"startDateStruct":471,"completionDateStruct":473,"leadSponsor":475,"locationsCount":4},"100594101","pathogenic-mechanisms-involved-in-the-initiation-and-progression-of-systemic-sclerosis-100594101","NCT07015060","Pathogenic Mechanisms Involved in the Initiation and Progression of Systemic Sclerosis","Inclusion Criteria:\n\n* Patients diagnosed with one of the following:\n\n  * Limited SSc\n  * Limited cutaneous SSc\n  * Diffuse cutaneous SSc\n* Patients followed regularly in consultations at CUSL.\n* Patients between ages 18-80.\n\nExclusion Criteria:\n\n* Other (co-occurring) autoimmune\u002Fautoinflammatory disease\n* Pregnancy\n* Participants with temporary or definitive disabilities to give consent\n* Participants unable to sign or read the inform consent form",{"count":463,"type":22},15,[25],"Identify rare variants in candidate genes and pathways identified in familial SSc, in patients with sporadic SSc.\n\nPerform (spatial) transcriptomic and proteomic analyses of affected skin from patients with and without cutaneous fibrosis, for the patterns and levels of expression\u002Factivation of candidate genes and pathways.\n\nTest for dysregulation of expression\u002Factivation of candidate genes and pathways in live cells isolated from the blood and skin biopsy of patients, and for the impact of these dysregulations on cell appearance, behavior and function.",[467],"Scleroderma (Limited and Diffuse)","2025-06-02",{"date":470,"type":37},"2025-06-11",{"date":472,"type":22},"2025-06",{"date":474,"type":22},"2031-03",{"name":43,"class":44},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":16,"sex":417,"minAge":18,"maxAge":483,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":468,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":45},"100593003","eumetriosis-insights-into-the-pathogenesis-of-endometriosis-100593003","NCT07000786","EUmetriosis: Insights Into the Pathogenesis of Endometriosis","EUmetriosis","Inclusion Criteria:\n\n* Premenopausal\n* In spontaneous menstrual cycle (no hormonal treatments for the last 3 months)\n* Healthy or with a clear diagnosis of endometriosis via ultrasound, MRI or laparoscopy\n\nExclusion Criteria:\n\n* HIV or Hepatitis positive\n* Pregnancy","56 Years",{"count":226,"type":22},[25],"This study investigates epigenetic changes in menstrual effluent and plasma from women with endometriosis to identify potential non-invasive diagnostic biomarkers for the disease.",[488],"Endometriosis",{"date":490,"type":37},"2025-06-03",{"date":492,"type":37},"2025-05-12",{"date":494,"type":22},"2029-12-31",{"name":43,"class":44},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":54,"minAge":503,"maxAge":504,"enrollmentInfo":505,"targetDuration":507,"studyType":130,"phases":4,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":45},"100593013","medical-follow-up-of-new-cases-of-polyarthritis-in-children-and-young-adults-100593013","NCT07000916","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults","Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults. Optimization of Clinical Response, Remission, Quality of Life and Analysis of Prognostic Markers","Inclusion Criteria:\n\n* Diagnosis of juvenile idiopathic arthritis, rheumatoid arthritis and seronegative \u002F psoriatic \u002F undifferentiated arthritis, systemic lupus erythematosus or diffuse systemic sclerosis (ACR criteria).\n* Naïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nExclusion Criteria:\n\n* Treated for \\> 3 months\n* \\> 50 years old","2 Years","50 Years",{"count":506,"type":22},1000,"10 Years","Population:\n\nJuvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative \u002F psoriatic \u002F undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).\n\nNaïve to basic treatment OR treated for ≤ 3 months; except for patients with JIA.\n\nThese 5 cohorts will be subject to standardized clinical monitoring.",[510,511,512,513,514,515],"Juvenile Idiopathic Arthritis","Rheumatoid Arthritis","Psoriatic Arthritis","Systemic Lupus Erythematosus","Diffuse Systemic Sclerosis","Seronegative Arthritis","2025-05-22",{"date":490,"type":37},{"date":519,"type":37},"2013-09-11",{"date":521,"type":22},"2028-03-31",{"name":43,"class":44},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":18,"enrollmentInfo":531,"targetDuration":533,"studyType":130,"phases":4,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":542,"locationsCount":45},"100527569","cap48---autism-in-children-and-adolescents-100527569","NCT06149468","CAP48 - Autism in Children and Adolescents","CAP48 Medical Research Project: Autism Spectrum Disorders in Children and Adolescents","CAP48-ASD","Inclusion Criteria:\n\n* children\u002Fadolescents (under 18 years of age) who apply to an autism reference center or who are followed up in an autism reference center from French-speaking region of Belgium.\n\nExclusion Criteria:\n\n* refusal by the family to allow their child's data to be included in the database.",{"count":532,"type":22},500,"5 Years","Evaluation and follow-up of children diagnosed with an autism spectrum disorder in French-speaking Belgium in order to optimize diagnostic protocols, the quality of care required and its accessibility, and to determine the impact of an autism spectrum disorder on schooling, family and society.",[536],"Autism Spectrum Disorder",{"date":538,"type":37},"2025-05-29",{"date":540,"type":37},"2023-09-15",{"date":432,"type":22},{"name":43,"class":44},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":16,"sex":54,"minAge":549,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":45},"100592739","validation-of-a-parental-questionnaire-for-screening-children-for-neurovisual-disorders-100592739","NCT06997354","Validation of a Parental Questionnaire for Screening Children for Neurovisual Disorders","Inclusion Criteria:\n\n* Parents of a child aged between 3 and 12\n* Their mother tongue must be French, to ensure that they understand the questions asked in writing.\n\nControl group:\n\n\\- Children of the parents surveyed who do not present any medical, school or family developmental particularities.\n\nClinical group\n\n\\- Children of the parents interviewed who present warning signs of CVI reported by a multidisciplinary team specialized in visual impairment.\n\nExclusion Criteria:\n\n* no specific criteria (see inclusion criteria)","3 Years",{"count":288,"type":22},"Some children present visual difficulties linked not to damage to the eye, but to damage to the brain. This type of dysfunction of the visual cerebral pathways leads, for example, to difficulties in recognition, visuomotor coordination or visuo-spatial disorders. These highly specific disorders are known as \"cortical visual impairment\" (CVI). Despite their real impact on children's development, these disorders are still poorly diagnosed in the French-speaking world. As a result, follow-up and care for these children are poorly adapted. A better understanding of neurovisual disorders and the availability of validated tools in French are therefore essential. Indeed, it is currently considered that 3 to 4% of children aged four to six, i.e. around one child per kindergarten class, have a CVI following a neuro-logical lesion acquired in the perinatal period.\n\nBecause of the lack of a valid tool in French, the aim of the present study is to provide the results of a validation study of a parental questionnaire for screening children with warning signs of CVI in French. This questionnaire will be offered online using the Qualtrics tool. In order to evaluate the relevance of this questionnaire, it will be proposed, on the one hand, to parents whose child (aged 3 to 12) does not present any particular developmental difficulties, and on the other hand, to parents whose child (aged 3 to 12) seems to present signs of neurovisual disorders. By comparing their answers, the investigators hope that certain questions will reveal elements typical of neurovisual disorders\u002FCVI, thus demonstrating the relevance of this questionnaire in facilitating diagnosis.",[553],"Children Suffering From Cortical Visual Impairment","2025-05-21",{"date":556,"type":37},"2025-05-30",{"date":558,"type":37},"2025-04-01",{"date":34,"type":22},{"name":43,"class":44},{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":130,"phases":4,"briefSummary":571,"conditions":572,"keywords":575,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":455},"100591887","ckd-cachexia-and-gut-microbiome-100591887","NCT06986265","CKD Cachexia and Gut Microbiome","Association of Cachexia and Gut Microbiome in Dialysis Patients : Investigation of the Interactions With Uremic Toxins and Inflammation.","DYNAMICA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of kidney failure (stage V)\n* Maintenance dialysis for at least 3 months\n* Understanding of the trial procedures and ability to adhere to the trial protocol\n\nExclusion Criteria:\n\n* Severe nonadherence to the dialysis procedure\n* Life expectancy below 1 year\n* Chronic inflammatory disease of the digestive tract (Crohn's disease, ulcerative colitis)\n* Bariatric surgery\n* Active cancer\n* Pregnancy\n* Antibiotics consumption in the month preceding the inclusion\n* Gastro-intestinal surgery, colonoscopy, or probiotics consumption in the 3 months preceding the inclusion\n* Drugs influencing body composition initiated ≤ 1 month : systemic corticosteroids, anabolic drugs as insulin or testosterone, post-menopausal hormone therapy, injectable contraceptives.\n* Known endocrinological disorders potentially leading to hypo- or hypermetabolism, untreated or treated for ≤ 1 month : disorders of thyroid gland, adrenal glands...\n* Patients under weight loss drugs : GLP1 agonists, orlistat",{"count":570,"type":22},157,"Cachexia is common in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality. Cachexia is a complex syndrome, in which inflammation and retention of uremic toxins are two main contributing factors. In this context, the role of the gut microbiome in CKD cachexia and the potential benefit of increasing the dialysis dose have been poorly explored. Here the investigators propose to study the links between cachexia and the gut microbiome, in association with inflammation and uremic toxins, in dialysis.\n\nThe specific objectives are the followings:\n\n1. Set up a prospective cohort of deeply characterized kidney failure patients treated with hemodialysis (in-center, self-care dialysis in a satellite unit and at home) and peritoneal dialysis, including evaluation of cachexia, body composition, collection of feces and blood to characterize the gut microbiota, measure serum levels of uremic toxins and inflammatory markers, with a longitudinal follow-up.\n2. To compare cachectic versus non-cachectic dialysis patients in terms of gut microbiota, inflammatory markers, level of uremic toxins, muscle transcriptome, dialysis dose and modality. In a subgroup analysis, the investigators plan to compare the different techniques of dialysis (in-center vs home-hemodialysis vs peritoneal dialysis).",[573,574],"Chronic Kidney Diseases","Cachexia",[576,577,578,579,580],"cachexia","Protein energy wasting","microbiota","chronic kidney disease","dialysis","2025-05-15",{"date":516,"type":37},{"date":584,"type":37},"2025-02-04",{"date":586,"type":22},"2030-12",{"name":43,"class":44},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":593,"acronym":594,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":54,"minAge":18,"maxAge":596,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":603,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":605,"lastUpdatePostDateStruct":606,"startDateStruct":608,"completionDateStruct":610,"leadSponsor":611,"locationsCount":236},"100587700","implementation-of-a-habit-ile-intervention-at-william-lennox-neurological-hospital-neureha---adult-100587700","NCT06931795","Implementation of a HABIT-ILE Intervention at William Lennox Neurological Hospital (NeuREHA) - Adult","Implementation of a HABIT-ILE Intervention at the William Lennox Neurological Centre for Sub-acute Adult Post-stroke Patients (\u003C6 Mois): a Randomised Controlled Trial","Ad-NeuREHA","Inclusion Criteria:\n\n* Phase aiguë ou subaiguë\n\nExclusion Criteria:\n\n* Epilepsie instable\n* Absence à déterminer sa volonté à participer\n* Traitement toxine pendant le stage","95 Years",{"count":598,"type":22},40,[25],"Using a randomized controlled trial design, in an hospital environment, possible changes induced by the \"Hand-arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE)\" treatment program will be investigated in functional activities of daily living, motor and cognitive assessment of patients with sub-acute post-stroke",[602],"Stroke",[604],"stroke, intensive intervention, motor skill learning, subacute","2025-04-09",{"date":607,"type":37},"2025-04-17",{"date":609,"type":22},"2025-04-15",{"date":188,"type":22},{"name":43,"class":44},""]